ODAC votes in favor of two CAR T-cell therapies for MM after weighing FDA concerns about early deaths – The Cancer Letter
The FDA Oncologic Drugs Advisory Committee voted overwhelmingly in favor of expanding the indications of two chimeric antigen receptor engineered T-cell therapies for multiple myeloma that showed improvement in progression-free survival, but also reported a higher number of early deaths on the experimental arm. To access this subscriber-only content please log in or renew your […]